TaiMed Biologics Inc’s (中裕新藥) sales of its Trogarzo HIV treatment are forecast to boom this year after the European Commission on Thursday last week approved it to be marketed, the company said yesterday.
The company plans to begin marketing the drug in Germany this year, as the nation has friendly regulations on drug pricing, allowing companies to market products before wholesale prices are finalized, TaiMed chief financial officer Jack Chen (陳怡成) said by telephone.
Company partner Montreal-based Theratechnologies Inc has begun making connections with hospitals and patients in Germany, targeting sales of the drug by the end of this year or at the beginning of next year, Chen said.
Theratechnologies — TaiMed’s exclusive marketing and distribution partner in more than 30 markets, including the US, Canada and the EU — is to negotiate prices with regulatory bodies in Europe, he said.
The European price has been estimated at 30 percent lower than US$118,000 for a year of treatment in the US, he said.
Trogarzo is a fourth-line treatment and a drug that is designed for people with multi-drug resistance, TaiMed said.
The number of people in Europe with HIV/AIDS who are multi-drug resistant, which means they require alternative treatments, is estimated to be between 20,000 and 25,000, Chen said.
TaiMed is to pay US$5 million to US-based Genentech Inc as a milestone payment, as Genentech developed and licensed the antibody ibalizumab (TMB-355), a key ingredient of Trogarzo.
TaiMed posted revenue of NT$283 million (US$9.12 million) in the first half of this year and expects its full-year revenue to reach NT$800 million thanks to stable sales of Trogarzo in the US, Chen said, adding that the company started marketing the drug in the US in April last year.
It reported a non-operating loss of NT$43 million in the first half, due to a drop in the value of its stake in Theratechnologies, Chen said.
Gross margin fell to 17 percent for the first six months due to low production yield at contract manufacturer WuXi Biologics Co (無錫生物製藥), which is responsible for the production of Trogarzo, Chen said, adding that the yield improved in the third quarter.
Merida Industry Co (美利達) has seen signs of recovery in the US and European markets this year, as customers are gradually depleting their inventories, the bicycle maker told shareholders yesterday. Given robust growth in new orders at its Taiwanese factory, coupled with its subsidiaries’ improving performance, Merida said it remains confident about the bicycle market’s prospects and expects steady growth in its core business this year. CAUTION ON CHINA However, the company must handle the Chinese market with great caution, as sales of road bikes there have declined significantly, affecting its revenue and profitability, Merida said in a statement, adding that it would
MARKET LEADERSHIP: Investors are flocking to Nvidia, drawn by the company’s long-term fundamntals, dominant position in the AI sector, and pricing and margin power Two years after Nvidia Corp made history by becoming the first chipmaker to achieve a US$1 trillion market capitalization, an even more remarkable milestone is within its grasp: becoming the first company to reach US$4 trillion. After the emergence of China’s DeepSeek (深度求索) sent the stock plunging earlier this year and stoked concerns that outlays on artificial intelligence (AI) infrastructure were set to slow, Nvidia shares have rallied back to a record. The company’s biggest customers remain full steam ahead on spending, much of which is flowing to its computing systems. Microsoft Corp, Meta Platforms Inc, Amazon.com Inc and Alphabet Inc are
RISING: Strong exports, and life insurance companies’ efforts to manage currency risks indicates the NT dollar would eventually pass the 29 level, an expert said The New Taiwan dollar yesterday rallied to its strongest in three years amid inflows to the nation’s stock market and broad-based weakness in the US dollar. Exporter sales of the US currency and a repatriation of funds from local asset managers also played a role, said two traders, who asked not to be identified as they were not authorized to speak publicly. State-owned banks were seen buying the greenback yesterday, but only at a moderate scale, the traders said. The local currency gained 0.77 percent, outperforming almost all of its Asian peers, to close at NT$29.165 per US dollar in Taipei trading yesterday. The
The US overtaking China as Taiwan’s top export destination could boost industrial development and wage growth, given the US is a high-income economy, an economist said yesterday. However, Taiwan still needs to diversify its export markets due to the unpredictability of US President Donald Trump’s administration, said Chiou Jiunn-rong (邱俊榮), an economics professor at National Central University. Taiwan’s exports soared to a record US$51.74 billion last month, driven by strong demand for artificial intelligence (AI) products and continued orders, with information and communication technology (ICT) and audio/video products leading all sectors. The US reclaimed its position as Taiwan’s top export market, accounting for
RSS